13:01 , Jul 1, 2019 |  BC Extra  |  Financial News

Versant, Bayer bet big on iPS cells to tackle price, efficacy of CAR therapies

Looking to tap allogeneic iPS cells to address the shortcomings of CAR cell therapies, Bayer and Versant Ventures launched Century Therapeutics on Monday with $250 million in funding. It’s the second time the partners have...
02:28 , Mar 9, 2018 |  BC Innovations  |  Product R&D

Chips for tox

After several years’ pushing from FDA, NIH and DARPA for more predictive preclinical tox tests, organ-on-a-chip companies are close to demonstrating their models can detect signals missed in animals. While replacing animals is nowhere in...
01:19 , Feb 16, 2018 |  BC Innovations  |  Product R&D

Banking on the placenta

Celgene Corp. spinout Celularity Inc. is aiming to disrupt the stem cell market with a platform of placenta-based cell therapies whose intrinsic allo-tolerance could provide a broadly applicable system for propelling off-the-shelf cancer therapies into...
23:17 , Oct 5, 2017 |  BC Innovations  |  Product R&D

Avidly specific

With its first two programs headed for the clinic next year, AvidBiotics Corp. is seeing the fruits of its move to human therapeutics from food safety and animal health. Using engineered peptides, the company has...
19:45 , Apr 21, 2017 |  BioCentury  |  Emerging Company Profile

Orchard’s pickings

Orchard Therapeutics Ltd. ’s autologous stem cell therapies could improve upon more advanced cell and gene therapies that also were designed to produce durable responses by restoring production of missing enzymes in rare genetic diseases....
07:00 , Aug 21, 2014 |  BC Innovations  |  Targets & Mechanisms

Corneal perspectives

Two independent findings could increase the availability of tissue for corneal transplants. A University of California, San Diego -led team has created a new source of limbal stem cells-which are needed for clear vision-by expressing...
07:00 , Jul 21, 2014 |  BC Week In Review  |  Company News

Cell Source, Cell Source deal

Cell Source Ltd. reverse-merged with Cell Source Inc. (formerly Ticket To See Inc.). Cell Source Ltd. shareholders own 78.5% of the combined company, while shareholders of Cell Source Inc. will own the remaining 21.5%. The...
07:00 , Jun 30, 2014 |  BioCentury  |  Product Development

Mending the majority

The much anticipated Phase III data for the combination of lumacaftor and Kalydeco ivacaftor from Vertex Pharmaceuticals Inc. didn't disappoint. Investors boosted the biotech's market cap by $6.4 billion, or 40%, on data that could...
08:00 , Nov 21, 2013 |  BC Innovations  |  Tools & Techniques

Naive human iPS cells

The inability to generate fully undifferentiated human induced pluripotent stem cells in vitro has dogged the development of stem cell-based platforms because the residual lineage bias of the cells most likely contributes to the inefficiency...
07:00 , Aug 1, 2013 |  BC Innovations  |  Tools & Techniques

The liver's new bud

Yokohama City University and Sekisui Medical Co. Ltd. researchers have produced vascularized human liver tissue that displays promising metabolic and regenerative capacity in mice. 1 The team now aims to scale up the procedure to...